Curis Earnings Call: Clinical Momentum Amid Revenue Void

Curis Inc. ((CRIS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Curis’ latest earnings call struck a cautiously optimistic tone, blending clear clinical momentum with a cleaner balance sheet but also underscoring new revenue and execution risks. Management highlighted regulatory alignment for its lead PCNSL program, encouraging early AML data, and disciplined cost cuts, while warning that the loss of legacy revenue and reliance on milestone‑linked financing leave little room for missteps.

Registrational PCNSL Study Gains FDA and EMA Support

Curis confirmed that its TakeAim Lymphoma trial in PCNSL is now positioned as a single‑arm registrational study using overall response rate as the primary endpoint. The company reported constructive talks with both the FDA and EMA, expects the study to support accelerated approvals in the U.S. and Europe, and projects full enrollment in 12–18 months with a potential regulatory filing window in 2027 after around six months of follow‑up.

AML Triplet Shows Early but Promising MRD Conversion

At the ASH meeting, Curis showcased early data from its AML triplet regimen combining emavusertib, azacitidine, and venetoclax. Among eight evaluable patients, five achieved MRD conversion, a 62.5% rate that management described as an encouraging initial efficacy signal, hinting that emavusertib could deepen responses when layered onto current standards in a difficult‑to‑treat setting.

CLL Proof‑of‑Concept Study Targets Deeper Responses

The company has moved emavusertib into CLL, launching a proof‑of‑concept study that adds the drug to BTK inhibitors in order to convert partial responses into complete remissions and MRD‑negative states. Site activation is underway in the U.S. and Europe, and Curis is guiding to initial clinical readouts at the ASH Annual Meeting in December 2026, positioning CLL as a key future value driver.

Full‑Year Net Loss Sharply Narrows in 2025

On the financial front, Curis reported a dramatic improvement in its full‑year bottom line, with the 2025 net loss shrinking to $7.6 million from $43.4 million in 2024, an 82.6% year‑over‑year reduction. Management framed this step‑change as evidence of tighter spending discipline and portfolio focus around emavusertib, even as revenue from legacy assets rolls off.

Q4 Swing to Profit Masked by One‑Time Gain

The company posted Q4 2025 net income of $19.4 million, or $1.23 per share, compared with a $9.6 million loss in the prior‑year quarter, but the apparent profitability was driven by accounting rather than operations. The quarter included a $27.2 million one‑time non‑cash gain tied to the sale of Erivedge, leaving investors with limited visibility into when, or if, Curis can generate sustainable earnings from its core pipeline.

Operating Costs Fall and Cash Runway Extends to 2027

Curis continued to pare back spending, with Q4 R&D dropping to $5.8 million from $9.0 million and full‑year R&D falling to $28.3 million from $38.6 million, while G&A declined both in the quarter and for the year. Combined with existing cash, $20.2 million received in January 2026, and the potential for another $20.2 million via warrant exercise, management believes it has funding to carry current plans into 2027.

Loss of Legacy Revenue Creates New Top‑Line Void

The flip side of the Erivedge divestiture is a near‑total disappearance of recurring revenue, which effectively ended in November 2025. Executives cautioned that they expect no meaningful revenue contribution in 2026 or beyond under the current plan, reinforcing that Curis is now a pure development‑stage story reliant on external capital rather than operating cash flow.

Q4 Profitability Not Yet a Repeatable Business Trend

Management emphasized that the Q4 2025 profit should not be extrapolated as a new normal, since it was largely a function of the non‑cash Erivedge gain rather than improved commercial performance. With the company still in the trial‑funding phase and without product sales, earnings are likely to revert to losses until a successful approval and launch can change the equation.

PCNSL Enrollment Headwinds Could Pressure Timelines

Despite describing TakeAim Lymphoma enrollment as on track, Curis acknowledged that PCNSL is an extremely rare non‑Hodgkin lymphoma subtype, leading to “choppy” recruitment of roughly zero to three patients per month. This dynamic raises the risk that enrollment could drag beyond the guided 12–18 months, potentially stretching the 2027 filing goal if screening and site expansion do not offset the scarcity of eligible patients.

Contingent Financing and Program Prioritization Risks

The company’s funding plan depends in part on the exercise of Series B warrants, which will be triggered only after the fifth CLL patient is dosed in the new study. To conserve cash, Curis is prioritizing PCNSL and CLL, while the AML program may see slower advancement until incremental resources arrive, creating a tradeoff between near‑term balance‑sheet security and broader pipeline velocity.

Guidance Centers on PCNSL Pathway, CLL Milestones, and Cash Discipline

Looking ahead, Curis reiterated guidance that TakeAim Lymphoma should complete enrollment in roughly 12–18 months, with the design expected to support accelerated submissions in both the U.S. and Europe and a potential filing window around 2027. Management is targeting initial CLL proof‑of‑concept data at ASH, aims to build on the early AML MRD conversion signal, and plans to keep R&D and G&A lean, guiding that its current and contingent cash resources should fund operations into 2027 even without new revenue streams.

Curis’ earnings call painted a picture of a leaner, more focused biotech pushing a single molecule across multiple blood cancers while navigating the typical funding and enrollment challenges of late‑stage development. For investors, the near‑term story hinges on execution in PCNSL and CLL, the durability of cost control, and whether the promising early efficacy signals can ultimately translate into approvals and a path to real, recurring revenue.